Cullinan Therapeutics, Inc.
CGEM
$20.34
$0.703.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -53.70M | -49.66M | -50.71M | -50.61M | -70.06M |
| Total Depreciation and Amortization | 79.00K | 79.00K | 79.00K | 79.00K | 77.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.89M | 6.84M | 6.38M | 8.11M | 8.18M |
| Change in Net Operating Assets | 7.51M | -3.30M | 6.14M | 5.55M | 4.19M |
| Cash from Operations | -38.22M | -46.05M | -38.11M | -36.88M | -57.61M |
| Capital Expenditure | -- | -- | -11.00K | -38.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 40.68M | 32.41M | 22.40M | 67.43M | 53.40M |
| Cash from Investing | 40.68M | 32.41M | 22.39M | 67.39M | 53.40M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.10M | 380.00K | 715.00K | 0.00 | 373.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.10M | 380.00K | 715.00K | 0.00 | 373.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.56M | -13.25M | -15.00M | 30.52M | -3.84M |